Results 1 to 10 of about 3,066 (135)

Evaluation of the real-world safety of eptifibatide in the treatment of ARDS: results of a disproportionality analysis of FAERS data [PDF]

Frontiers in Medicine
BackgroundAcute respiratory distress syndrome (ARDS) is a clinical syndrome with an extremely high mortality rate, and antiplatelet therapy is an important treatment approach.
Peng Zhang, Wenjing Wang, Ting Zhao, Guoping Wang, Fanyong Shang, Feng Ji   +5 more
doaj   +2 more sources

Administration of eptifibatide as rescue therapy during mechanical thrombectomy in acute ischemic stroke [PDF]

Frontiers in Neurology
BackgroundThe success of the technical implementation of mechanical thrombectomy (MT) depends on many factors. Considering the experience of the interventional radiologist and the anatomical vascular differences of individual patients, it has technical ...
David Cernik, David Cernik, Jiri Neumann, Jarmila Neradova, Veronika Hlinena, Pavol Viglas, Pavol Viglas, David Cihlar, Filip Cihlar   +8 more
doaj   +2 more sources

Adaptive Antithrombotic Strategy for Tandem Occlusion Stroke: Escalating Therapy After Thrombectomy and Stenting [PDF]

Diagnostics
Background/Objectives: There is no consensus on standardized treatment algorithms for patients with acute ischemic stroke due to anterior circulation tandem occlusions.
Gregory Howaldt, Mara Thut, Miklos Krepuska, Patrick Thurner, Jawid Madjidyar, Anna Kyselyova, Susanne Wegener, Christoph Globas, Andreas Luft, Tilman Schubert, Lars Michels, Zsolt Kulcsar   +11 more
doaj   +2 more sources

Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience [PDF]

BMC Cardiovascular Disorders
Background We evaluated the safety and effectiveness of combined eptifibatide and ticagrelor in patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI).
Shangsong Shi, Zicheng Ling, Shaohua Gu, Tingbo Jiang, Lin Ling   +4 more
doaj   +2 more sources

Adjunctive Eptifibatide Administration in ACS Patients Undergoing Percutaneous Coronary Intervention: A Randomized Comparison of Bolus-only Versus Standard Therapy [PDF]

American Heart Journal Plus
Background: Guidelines do not recommend routine glycoprotein IIb/IIIa inhibitors (GPIs), reserving them for high thrombotic-risk or bailout cases. Most acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) are already
Fatemeh Baharvand, Maedeh Dadras, Arsalan Salari, Shiva Parvaneh, Asieh Ashouri, Fatemeh Mirrazeghi, Amir Aris, Yaser Jenab   +7 more
doaj   +2 more sources

Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Antiplatelet drugs represent potential candidates for protecting the penumbral microcirculation during cerebral ischemia and improving the benefits of arterial recanalization in ischemic stroke.
Sébastien Dupont, Héloïse Lebas, Sabrina Mavouna, Eloïse Pascal, Astride Perrot, Adrien Cogo, Marie‐Charlotte Bourrienne, Carine Farkh, Mialitiana Solo Nomenjanahary, Véronique Ollivier, Fatima Zemali, Bernhard Nieswandt, Stéphane Loyau, Martine Jandrot‐Perrus, Eric Camerer, Jean‐Philippe Desilles, Mikael Mazighi, Yacine Boulaftali, Benoît Ho‐Tin‐Noé   +18 more
doaj   +2 more sources

Eptifibatide bolus dose postductal stenting intervention: A single-center experience [PDF]

Annals of Pediatric Cardiology
Objectives: Stent thrombosis, a potential complication of ductal stenting, is associated with high mortality. This is a catastrophic complication, which can occur acutely (within 24 h), subacutely (within 30 days), or late (≥30 days) after stent ...
Rishika Mehta, Amitabha Chattopadhyay, Aritra Mukherji, Sanjiban Ghosh, Jayita Nandy Das, Pushpanjali Gupta   +5 more
doaj   +2 more sources

Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage

Case Reports in Critical Care, 2021
Background. Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests antibody-dependent
Gregory Byrd, Sabina Custovic, David Byrd, Deanna Ingrassia Miano, Jasdeep Bathla, Antonious Attallah   +5 more
doaj   +1 more source

Results of a pilot clinical trial of the safety and efficacy of an original glycoprotein IIb/IIIa receptor inhibitor in acute coronary syndrome

Кардиоваскулярная терапия и профилактика, 2023
Aim. To study the safety and efficacy of Angipure in acute ST-segment elevation coronary syndrome (STE-ACS) and high-risk percutaneous transluminal coronary angioplasty (PTCA) compared with eptifibatide.Material and methods.
S. V. Lukyanov, Yu. F. Glukhov, E. V. T., B. M. Tankhilevich, D. A. Zateyshchikov, T. V. Khlevchuk, I. B. Bondareva   +6 more
doaj   +1 more source

Application of eptifibatide injection in acute ischemic cerebrovascular disease [PDF]

Xin yixue, 2022
Objective To evaluate the treatment effectiveness and safety of eptifibatide injection in the treatment of acute ischemic cerebrovascular disease （ICVD）.
Mei Ni, Tian Liang
doaj   +1 more source